MCL Literature Feed

Seven-year follow-up of venetoclax-ibrutinib in relapsed/refractory MCL shows durable responses (30% PFS) and demonstrates feasibility of MRD-guided treatment-free remission, supporting a long-term chemotherapy-free strategy.

A survey of US and European hematologists reveals significant knowledge gaps in MCL guidelines, molecular testing, and toxicity management, highlighting a need for improved continuing medical education.

This large, real-world French database study on ibrutinib focuses exclusively on patients with CLL, providing no specific data or insights relevant to mantle cell lymphoma.

This case report describes the rare but life-threatening development of disseminated intravascular coagulation (DIC) in a patient with the typically indolent, asymptomatic leukemic non-nodal variant of MCL.

This case report details the practical challenges and potential toxicities of administering CAR-T cell therapy to an elderly MCL patient with high tumor burden, informing management of this high-risk group.

This case report identifies life-threatening aplastic anemia as a rare but fatal toxicity of acalabrutinib in MCL, urging clinicians to consider it in patients developing pancytopenia.

This meta-analysis of phase 2/3 trials quantifies venous thromboembolism risk after CAR-T therapy, providing crucial data to guide thromboprophylaxis strategies in MCL patients.

Preclinical data show combining a BCL-XL inhibitor with venetoclax overcomes resistance in MCL models, even in BIM-deficient cells, suggesting a new strategy for venetoclax-refractory patients.

This paper likely provides a retrospective or real-world analysis of the incidence, types, and risk factors for infections in MCL, informing clinical decisions on prophylaxis and supportive care.

Bendamustine is a feasible alternative lymphodepletion for brexu-cel in MCL, showing comparable efficacy to standard cy/flu with less cytopenia, providing a critical option during drug shortages.

A qualitative study of Japanese MCL patients reveals that convenience, quality of life, and shared decision-making are key treatment preferences, alongside efficacy and safety, guiding personalized care.

In a large real-world cohort, mantle cell lymphoma patients exhibited higher CAR19 expansion than other lymphomas, which directly correlated with increased toxicity and significantly higher steroid requirements.

An 85-year-old MCL patient on ibrutinib developed a cutaneous EBV+ NK/T-cell lymphoma that resolved spontaneously, highlighting a rare, potentially indolent lymphoproliferative disorder in this treatment setting.

Adding bortezomib to R-HAD chemotherapy for relapsed/refractory MCL significantly improved time to treatment failure (12 vs 2.6 months), providing a valuable option when BTK inhibitors are unavailable.

A steroid-sparing regimen of doxycycline, cetirizine, and valacyclovir successfully managed exaggerated mosquito bite reactions in an indolent MCL patient, offering a novel approach for this rare cutaneous manifestation.

This UK real-world, intention-to-treat analysis of brexu-cel confirms high efficacy in infused patients but reveals a 30% attrition rate before infusion and significant non-relapse mortality from infection.

This case report demonstrates delayed Hepatitis B reactivation with acalabrutinib in relapsed MCL, underscoring the need for viral screening and prophylaxis with second-generation BTK inhibitors.

This case report links MCL with Henoch-Schönlein purpura and IgA-nephritis, highlighting a rare paraneoplastic syndrome with specific dermatological and renal manifestations for clinicians to recognize.

This review summarizes the clinical data and rationale for targeted agents like BTK and BCL2 inhibitors, highlighting the paradigm shift away from chemotherapy in both relapsed/refractory and frontline MCL.

This preclinical study elucidates acalabrutinib's metabolic pathways, identifying reactive intermediates that may explain potential drug-drug interactions, toxicities, or off-target effects in patients with MCL.

This review details the evolution of BTK inhibitors, highlighting improved toxicity with newer agents and the emergence of non-covalent BTKis and novel resistance mutations, impacting MCL treatment sequencing.

This commentary discusses the zandelisib (PI3Ki) plus zanubrutinib (BTKi) combination, suggesting a potential role for newer, potentially less toxic PI3K inhibitors in relapsed/refractory MCL.

In a European compassionate use program, pirtobrutinib demonstrated a 67% overall response rate and good safety in heavily pretreated, BTKi-exposed relapsed/refractory MCL, supporting its real-world clinical utility.

This case report details severe glofitamab-induced ICANS with seizures in a heavily pre-treated MCL patient, highlighting CNS risk factors and successful management with anakinra and antiseizure drugs.

Brexucabtagene autoleucel (CAR-T) combined with BTK inhibitors is a potentially safe and effective strategy for treating relapsed mantle cell lymphoma with central nervous system involvement.

The PI3Ki zandelisib plus BTKi zanubrutinib combination shows high efficacy (74% ORR, 47% CR) with manageable toxicity in relapsed/refractory MCL, offering a promising chemotherapy-free regimen.

The EHA/EBMT ICAHT grading system better predicts severe infections and mortality post-CAR-T than CTCAE, which is highly relevant as MCL patients showed the highest rates of severe hematotoxicity.

The CAR-T therapy lisocabtagene maraleucel demonstrates high, durable complete responses and a favorable safety profile in heavily pretreated, relapsed/refractory MCL, including high-risk patients.

This case report highlights unprovoked venous thromboembolism as a presenting symptom of mantle cell lymphoma, underscoring the need for a prompt malignancy workup in such clinical scenarios.

This article summarizes Israeli national guidelines for administering CAR-T therapy in relapsed/refractory MCL, detailing patient management, toxicity monitoring for CRS and ICANS, and long-term follow-up principles.